Cargando…
Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes
BACKGROUND: Multiple phase I-II clinical trials have reported on the efficacy and safety of prostate stereotactic body radiotherapy (SBRT) for the treatment of prostate cancer. However, few have reported outcomes for prostate SBRT using periprostatic hydrogel spacer (SpaceOAR; Augmenix). Herein, we...
Autores principales: | Hwang, Mark E., Mayeda, Mark, Liz, Maria, Goode-Marshall, Brenda, Gonzalez, Lissette, Elliston, Carl D., Spina, Catherine S., Padilla, Oscar A., Wenske, Sven, Deutsch, Israel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679492/ https://www.ncbi.nlm.nih.gov/pubmed/31375119 http://dx.doi.org/10.1186/s13014-019-1346-5 |
Ejemplares similares
-
Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function
por: Hwang, Mark E, et al.
Publicado: (2021) -
A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy
por: Hwang, Mark E, et al.
Publicado: (2018) -
Periprostatic venous thrombosis
por: Paulino, Eduardo, et al.
Publicado: (2016) -
Plan comparison of prostate stereotactic radiotherapy in spacer implant patients
por: Oki, Yuya, et al.
Publicado: (2021) -
Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison
por: Ogita, Mami, et al.
Publicado: (2021)